The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy
Open accessAbstract
The ability of cancer cells to escape from the natural or immunotherapy‐induced antitumor immune response is often associated with alterations in the tumor cell surface expression of Major Histocompatibility Complex (MHC) Class I antigens. Considerable knowledge has been gained on the prevalence of various patterns of MHC Class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data are available on the changes in MHC Class I expression happening during the course of cancer immunotherapy. We have recently proposed that the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy could be predetermined by the molecular mechanism responsible for the MHC Class I alteration and not by the type of immunotherapy used, i.e., interleukin‐2 (IL‐2), Bacillus Calmette‐Guèrin (BCG), interferon‐alpha (IFN‐α), peptides alone, dendritic cells loaded with peptides, protein‐bound polysaccharide etc. If the molecular alteration responsible for the changes in MHC Class I expression is reversible by cytokines (“soft” lesion), the MHC Class I expression will be upregulated, the specific T cell–mediated response will increase and the lesion will regress. However, if the molecular defect is structural (“hard” lesion), the MHC Class I expression will remain low, the escape mechanism will prevail and the primary tumor or the metastatic lesion will progress. According to this idea, the nature of the preexisting MHC Class I lesion in the cancer cell has a crucial impact determining the final outcome of cancer immunotherapy. In this article, we discuss the importance of these two types of molecular mechanisms of MHC Class I–altered expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 1×
“The T cell response and the tumor growth will probably reach an equilibrium.(71) This equilibrium is broken when a particular immunotherapeutic pro-”
BackgroundMarincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Self-citationMechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 465
Natural history of HLA expression during tumour development
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., & Stern, P. L. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90264-l · Cited by 448
Self-citationHLA : genetic diversity of HLA functional and medical implication
Charron, D. J. (1997) · Medical Entomology and Zoology · Cited by 354
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346
D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci114984 · Cited by 309
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279
Meissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., & Seliger, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2146 · Cited by 266
Watson, N. F. S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21303 · Cited by 254
Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239
Self-citationChen, H. L., Gabrilovich, D., Tampé, R., Girgis, K. R., Nadaf, S., & Carbone, D. P. (1996) · Nature Genetics · doi:10.1038/ng0696-210 · Cited by 203
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
IGF-I and IGF-II in relation to colorectal cancer
Manousos, O. N., Souglakos, J., Bosetti, C., Τζώνου, Α., Chatzidakis, V., Trichopoulos, D., Adami, H., & Mantzoros, C. S. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<91::aid-ijc17>3.0.co;2-4 · Cited by 190
Seliger, B., Ritz, U., Abele, R., Bock, M., Tampé, R., Sutter, G., Drexler, I., Huber, C., & Ferrone, S. (2001) · PubMed · Cited by 189
Kloor, M., Becker, C., Benner, A., Woerner, S. M., Gebert, J., Ferrone, S., & von Knebel Doeberitz, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0044 · Cited by 178
Vitale, M., Rezzani, R., Rodella, L. F., Zauli, G., Grigolato, P., Cadei, M., Hicklin, D. J., & Ferrone, S. (1998) · PubMed · Cited by 174
Cabrera, C. M., Jiménez, P., Cabrera, T., Esparza, C., Ruiz‐Cabello, F., & Garrido, F. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00020.x · Cited by 164
Self-citationKruit, W. H. J., van Ojik, H. H., Brichard, V. G., Escudier, B. J., Dorval, T., Dréno, B., Patel, P. M., van Baren, N., Avril, M., Piperno‐Neumann, S., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21264 · Cited by 160
Garrido, F., FESTENSTEIN, H., & Schirrmacher, V. (1976) · Nature · doi:10.1038/261705a0 · Cited by 149
Self-citationBenitez, R., Godelaine, D., López‐Nevot, M. Á., Brasseur, F., Jimenez, P., Marchand, M.-C., Oliva, M. R., van Baren, N., Cabrera, T., Andry, G., et al. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03082.x · Cited by 149
Self-citationRomero, J. M., Jiménez, P., Cabrera, T., Cózar, J. M., Pedrinaci, S., Tallada, M., Garrido, F., & Ruiz‐Cabello, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20499 · Cited by 140
Self-citationHla Class I Antigens in Human Tumors
Garrido, F., Cabrera, T., López‐Nevot, M. Á., & Ruiz‐Cabello, F. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60713-7 · Cited by 134
Self-citationCarretero, R., Romero, J. M., Ruiz‐Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128
Self-citationLópez‐Nevot, M. Á., Esteban, F., FERRON, A. D., Gutiérrez, J., Mr, O., Romero, C., Huelin, C., Ruiz‐Cabello, F., & Garrido, F. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.45 · Cited by 127
Self-citationTumour immunology: MHC antigens and malignancy
FESTENSTEIN, H., & Garrido, F. (1986) · Nature · doi:10.1038/322502a0 · Cited by 121
Self-citationAnalysis of HLA expression in human tumor tissues
Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119
Self-citationSeliger, B., Atkins, D., Bock, M., Ritz, U., Ferrone, S., Huber, C., & Störkel, S. (2003) · PubMed · Cited by 113
Ritz, U., Momburg, F., Pilch, H., Huber, C. G., Maeurer, M. J., & Seliger, B. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.6.1211 · Cited by 111
Maleno, I., López‐Nevot, M. Á., Cabrera, T., Jose, S., & Garrido, F. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0296-0 · Cited by 111
Self-citationWang, Z., Marincola, F. M., Rivoltini, L., Parmiani, G., & Ferrone, S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.2.205 · Cited by 102
Mechanisms of loss of HLA class I expression on colorectal tumor cells
Browning, M. J., Petronzelli, F., Bicknell, D. C., Krausa, P., Rowan, A., Tonks, S., Murray, N., Bodmer, J. G., & Bodmer, W. F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02571.x · Cited by 101
Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors
Seliger, B., Ruiz‐Cabello, F., & Garrido, F. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00407-7 · Cited by 100
Self-citationRodríguez, T., Méndez, R., Campo, A. D., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz‐Cabello, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-34 · Cited by 98
Self-citationFeenstra, M., Veltkamp, M., van Kuik, J., Wiertsema, S. P., Slootweg, P. J., van den Tweel, J. G., de Weger, R. A., & Tilanus, M. G. J. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.540304.x · Cited by 98
Paschen, A., Méndez, R., Jimenez, P., Sucker, A., Ruiz‐Cabello, F., Song, M., Garrido, F., & Schadendorf, D. (2002) · International Journal of Cancer · doi:10.1002/ijc.10906 · Cited by 97
Self-citationMaleno, I., Cabrera, C., Cabrera, T., Paco, L., López‐Nevot, M. Á., Collado, A., Ferr�n, A., & Garrido, F. (2004) · Immunogenetics · doi:10.1007/s00251-004-0692-z · Cited by 96
Self-citationChang, C., Campoli, M. R., Restifo, N. P., Wang, X., & Ferrone, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1462 · Cited by 95
Godelaine, D., Carrasco, J., Lucas, S., Karanikas, V., Schuler‐Thurner, B., Coulie, P. G., Schuler, G., Boon, T., & Pel, A. V. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4893 · Cited by 93
Garcia-Lora, A. M., Martinez, M., Algarra, I., Gaforio, J. J., & Garrido, F. (2003) · International Journal of Cancer · doi:10.1002/ijc.11241 · Cited by 92
Self-citationWang, Z., Cao, Y., Albino, A. P., Zeff, R. A., Houghton, A., & Ferrone, S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116249 · Cited by 91
The Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 90
Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants
Garcia-Lora, A. M., Algarra, I., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<109::aid-ijc1017>3.0.co;2-e · Cited by 85
Self-citationCabrera, T., Lara, E., Romero, J. M., Maleno, I., Real, L. M., Ruiz‐Cabello, F., Valero, P. M., Camacho, F. M., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0226-7 · Cited by 83
Self-citationMéndez, R., Aptsiauri, N., Campo, A. D., Maleno, I., Cabrera, T., Ruiz‐Cabello, F., Garrido, F., & Garcia-Lora, A. M. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0701-z · Cited by 70
Self-citationAptsiauri, N., Carretero, R., Garcia-Lora, A. M., Real, L. M., Cabrera, T., & Garrido, F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0532-3 · Cited by 62
Self-citationLOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas
Maleno, I., Romero, J. M., Cabrera, T., Paco, L., Aptsiauri, N., Cózar, J. M., Tallada, M., López‐Nevot, M. Á., & Garrido, F. (2006) · Immunogenetics · doi:10.1007/s00251-006-0111-8 · Cited by 57
Self-citationAbril, E., Mendez, R. E., Garcia-Lora, A. M., Serrano, A., Cabrera, T., Garrido, F., & Ruiz‐Cabello, F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02574.x · Cited by 55
Self-citationVertuani, S., Triulzi, C., Roos, A., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0587-1 · Cited by 55
Progress in manual breast examination
Hall, D. C., Goldstein, M. K., & Stein, G. H. (1977) · Cancer · doi:10.1002/1097-0142(197707)40:1<36::aid-cncr2820400108>3.0.co;2-7 · Cited by 54
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines
Méndez, R., Rodríguez, T., Campo, A. D., Monge, E., Maleno, I., Aptsiauri, N., Jiménez, P., Pedrinaci, S., Pawelec, G., Ruiz‐Cabello, F., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0411-3 · Cited by 49
Self-citationA new β2 microglobulin mutation found in a melanoma tumor cell line
Pérez, B. F., Benitez, R., Fernández, M. A., Oliva, M. R., Soto, J. L., Serrano, S., López‐Nevot, M. Á., & Garrido, F. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530607.x · Cited by 49
Self-citationGarrido, F. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02570.x · Cited by 40
Self-citationCriteria to define HLA haplotype loss in human solid tumors
Ramal, L. M., Feenstra, M., Zwan, A. ‐. V. D., Collado, A., López‐Nevot, M. Á., Tilanus, M. G. J., & Garrido, F. (2000) · Tissue Antigens · doi:10.1034/j.1399-0039.2000.550507.x · Cited by 40
Self-citationCampo, A. B., Aptsiauri, N., Méndez, R., Zinchenko, S. P., Vales, Á., Paschen, A., Ward, S., Ruiz‐Cabello, F., González‐Aseguinolaza, G., & Garrido, F. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02276.x · Cited by 40
Self-citationPaschen, A., Arens, N., Sucker, A., Greulich‐Bode, K. M., Fonsatti, E., Gloghini, A., Striegel, S., Schwinn, N., Carbone, A., Hildenbrand, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2174 · Cited by 36
Serrano, A., Brady, C. S., Jimenez, P., Duggan-Keen, M. F., Méndez, R., Stern, P. L., Garrido, F., & Ruiz‐Cabello, F. (2000) · Immunogenetics · doi:10.1007/s002510000239 · Cited by 30
Self-citationJiménez, P., Cabrera, T., Méndez, R., Esparza, C., Cozar, J. M., Tallada, M., López‐Nevot, M. Á., Ruiz‐Cabello, F., & Garrido, F. (2001) · Immunogenetics · doi:10.1007/s002510100371 · Cited by 27
Self-citationCabrera, T., Maleno, I., Collado, A., López‐Nevot, M. Á., Tait, B. D., & Garrido, F. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00777.x · Cited by 25
Self-citationHigher HLA class I expression in renal cell carcinoma than in autologous normal tissue
Sáenz-López, P., Gouttefangeas, C., Hennenlotter, J., Concha, Á., Maleno, I., Ruiz‐Cabello, F., zar, J. M. C., Tallada, M., Stenzl, A., Rammensee, H., et al. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01409.x · Cited by 24
Self-citationChemInform Abstract: HLA and Cancer: 12th International Histocompatibility Workshop Study
Garrido, F., Cabrera, T., Accolla, R. S., et al. (2000) · ChemInform · doi:10.1002/chin.200027291 · Cited by 21
Self-citation
Cited by
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Self-citation
Metadata
- Authors
- Garrido, F., Cabrera, T., & Aptsiauri, N.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-05-13
- Volume
- 127
- Issue
- 2
- Pages
- 249-256
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2070030959
- Cited by
- 276
- References
- 68
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.